$82.97 1.6 2.0%
Last Trade - 15/01/21
| Market Cap | ÂŁ11.09bn |
| Enterprise Value | ÂŁ11.05bn |
| Revenue | ÂŁ1.37bn |
| Position in Universe | 664th / 6543 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 749.3 | 889.9 | 1,117 | 1,314 | 1,491 | 1,704 | 1,851 | 1,920 | +17.9% | ||
| -98.3 | ||||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | October 25, 1996 |
| Public Since | July 21, 2009 |
| No. of Shareholders: | 44 |
| No. of Employees: | 3,001 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 181,529,667 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 105 Digital Dr, NOVATO, 94949-8703, United States |
| Web | http://www.bmrn.com/ |
| Phone | +1 415 5066700 |
| Contact | () |
| Auditors | KPMG LLP |
As of 15/01/21, shares in Biomarin Pharmaceutical Inc are trading at $82.97, giving the company a market capitalisation of ÂŁ11.09bn. This share price information is delayed by 15 minutes.
Shares in Biomarin Pharmaceutical Inc are currently trading at $82.97 and the price has moved by -6.91% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biomarin Pharmaceutical Inc price has moved by -18.34% over the past year.
Of the analysts with advisory recommendations for Biomarin Pharmaceutical Inc, there are there are currently 6 "buy" , 9 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Biomarin Pharmaceutical Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Biomarin Pharmaceutical Inc is scheduled to issue upcoming financial results on the following dates:
Biomarin Pharmaceutical Inc does not currently pay a dividend.
Biomarin Pharmaceutical Inc does not currently pay a dividend.
Biomarin Pharmaceutical Inc does not currently pay a dividend.
To buy shares in Biomarin Pharmaceutical Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Biomarin Pharmaceutical Inc are currently trading at $82.97, giving the company a market capitalisation of ÂŁ11.09bn.
Here are the trading details for Biomarin Pharmaceutical Inc:
Based on an overall assessment of its quality, value and momentum, Biomarin Pharmaceutical Inc is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Biomarin Pharmaceutical Inc are currently priced at $82.97. At that level they are trading at 33.66% discount to the analyst consensus target price of 0.00.
Analysts covering Biomarin Pharmaceutical Inc currently have a consensus Earnings Per Share (EPS) forecast of 4.234 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biomarin Pharmaceutical Inc. Over the past six months, the relative strength of its shares against the market has been -44.56%. At the current price of $82.97, shares in Biomarin Pharmaceutical Inc are trading at -10.67% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biomarin Pharmaceutical Inc PE ratio based on its reported earnings over the past 12 months is 20.56. The shares are currently trading at $82.97.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biomarin Pharmaceutical Inc's management team is headed by:
Here are the top five shareholders of Biomarin Pharmaceutical Inc based on the size of their shareholding:
